Mounjaro®
Starting from £179.99/mo
Start journey Learn moreNo. Mounjaro is a once-weekly injection, and taking it more than once a week is not safe. Each pre-filled KwikPen releases tirzepatide into your system over seven days, and doubling up within that window does not speed up weight loss — it raises your risk of serious side effects without any clinical benefit. If you're wondering whether the once-weekly schedule can be adjusted to suit your life, the short answer is no: the dosing interval is fixed by the medicine's licence and by how tirzepatide works in the body. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber determines your schedule and any dose changes after a clinical assessment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Tirzepatide has a relatively long biological half-life of around five days. That means when you inject on, say, a Monday morning, measurable amounts of the medicine are still circulating the following Saturday. The once-weekly schedule is designed around this, by day seven, levels have dropped just enough that the next injection maintains a steady, therapeutic concentration without stacking. Inject again on Wednesday and you are adding a full dose on top of an already-active one.
The tirzepatide molecule works by activating both GIP and GLP-1 receptors, slowing gastric emptying and reducing appetite. That mechanism does not produce faster results with higher frequency; the effect is already running continuously. NHS guidance on the medicine confirms the once-weekly subcutaneous injection schedule at every dose level from 2.5 mg to 15 mg. If you want a plain-language overview of how Mounjaro works and its full licensed strengths, the NHS tirzepatide medicines page is a reliable starting point.
The practical upshot: more frequent dosing is not a shortcut to a higher effective dose. It is simply an overdose in timing terms, carrying more risk and no extra benefit.
The most likely immediate effects are gastrointestinal: nausea, vomiting, diarrhoea and stomach cramps become significantly more likely when tirzepatide concentrations spike above the intended range. These are already the most commonly reported side effects on the standard schedule, where they tend to settle within a week or two of starting or increasing a dose. Compress the dosing interval and you lose that adaptation window entirely.
Beyond tolerability, the MHRA's guidance on GLP-1 receptor agonist medicines flags that gastrointestinal illness severe enough to cause dehydration can put the kidneys under strain. Taking more than one dose a week risks pushing symptoms into territory where you need medical attention rather than simply waiting them out. If you ever experience severe, persistent stomach pain that spreads toward your back (whether on the standard schedule or not) that warrants urgent medical assessment, as this can be a sign of acute pancreatitis, which the MHRA has highlighted as an infrequent but serious risk with this class of medicines.
If you are curious whether taking Mounjaro a day or two early is different from taking it twice in a week, it is still not recommended, even a slightly shortened interval carries the same stacking risk, just to a lesser degree.
Mistakes happen. If you realise you have injected twice in one week, check the date on your pen, a quick look at the label takes under a minute and makes it easy to confirm exactly when you last dosed. Then contact your prescriber or, if you feel unwell, call 111 or seek medical advice promptly. Do not try to compensate by skipping the following week's dose without clinical guidance; that risks gaps in treatment that your prescriber needs to know about.
Going forward, a fixed injection day helps enormously. Many people tie it to a routine, a particular evening, or the same morning each week before work. If you find yourself confused about your schedule more than once, it is worth raising at your next clinical review. The question of pausing a week is also a common one, and the answer there is similarly nuanced, always a prescriber conversation, never a unilateral call.
Yes, but only within limits. If you need to shift your injection day (because your usual day clashes with a holiday, a medical procedure, or a change in routine) it is possible to move it, provided the new dose falls at least seven days after the previous one. That is the key rule: a minimum of seven days between injections, not a maximum. Giving yourself eight or nine days between doses on an occasional basis is less of a concern than going under seven days.
What you cannot do is take a second injection in the same week to "bank" an early dose before a trip, or take one early because you feel the previous dose wearing off. If you feel like the medicine is less effective as the week goes on, that is a conversation about your current dose level, not about frequency. Your prescriber can review whether titration to the next dose level is appropriate.
Mounjaro is a prescription-only medicine, and the dosing schedule is not something that should be self-adjusted. If your current regimen raises questions, our Mounjaro overview covers the full clinical picture, and you can read about how our prescribers approach treatment from the first consultation onward. You can also find broad context on medically supervised weight loss if you are weighing up your options more generally, including information on whether otc tirzepatide is something you might be eligible for depending on your circumstances.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.